This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Dana-Farber-Cancer Institute Inc., The Broad Institute, Inc., The General Hospital Corporation. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1,268 
1 out of 486 
1 out of 3,073 
Years Active: 2020
Title: Inventor Spotlight: Jing Sun
Introduction
Jing Sun, a talented inventor based in Brookline, Massachusetts, holds a significant patent in the field of cancer immunotherapy. Her innovation focuses on the development of a pharmaceutical composition that utilizes shared neoantigens, which are crucial for eliciting immune responses against tumors. This cutting-edge work has the potential to enhance cancer treatment strategies and improve patient outcomes.
Latest Patents
Jing Sun's notable patent involves a pharmaceutical composition comprising a plurality of neoantigenic peptides along with a pharmaceutically acceptable carrier. These peptides contain tumor-specific neoepitopes capable of binding to HLA proteins in individuals. Notably, the composition includes neoantigenic peptides derived from tumor-specific mutations that are prevalent in at least 1% of the cancer patient population, and peptides that can invoke an immune response against tumors prevalent in a minimum of 5% of the subjects. This innovation represents a significant step forward in personalized medicine and cancer treatment.
Career Highlights
Jing has built her career at prestigious institutions, including the Broad Institute and Dana-Farber Cancer Institute. Her work in these organizations has contributed immensely to advancements in cancer research and treatment modalities. Her innovative approach in deciphering neoantigenic peptides underscores her dedication to improving therapeutic strategies for cancer patients.
Collaborations
Throughout her career, Jing Sun has collaborated with prominent figures in her field, including Edward F. Fritsch and Nir Hacohen. These collaborations have fostered a rich environment for research and innovation, allowing for the exchange of ideas and the enhancement of cancer treatment methodologies.
Conclusion
Jing Sun’s contributions to the field of cancer research through her patent on shared neoantigens open new avenues for developing effective immunotherapies. Her dedication and innovative spirit are commendable, positioning her as a key figure in the ongoing fight against cancer. As researchers continue to explore the possibilities of her work, the potential impact on patient care and treatment outcomes remains promising.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile